| Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More | Frank Vinluan | 10/09/20 | National |
| In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug | Frank Vinluan | 10/08/20 | National |
| Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs | Frank Vinluan | 10/06/20 | Boston |
| Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B | Frank Vinluan | 10/05/20 | New York |
| Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More | Frank Vinluan | 10/02/20 | National |
| Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China | Frank Vinluan | 09/30/20 | New York |
| Orphazyme Stock Sale Reaps $83M as Neimann-Pick Drug Review Begins | Frank Vinluan | 09/29/20 | Europe |
| Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward | Frank Vinluan | 09/25/20 | Europe |
| Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More | Frank Vinluan | 09/25/20 | National |
| Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs | Frank Vinluan | 09/24/20 | Boston |
| Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal | Frank Vinluan | 09/21/20 | San Francisco |
| Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
| Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy | Frank Vinluan | 09/15/20 | Europe |
| Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals | Frank Vinluan | 09/14/20 | Seattle |
| Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout | Frank Vinluan | 09/14/20 | San Francisco |
| Grifols Moves Deeper Into Proteome R&D With $146M Deal for Alkahest | Frank Vinluan | 09/08/20 | San Francisco |
| AbbVie Strikes Deal for I-Mab Drug With a Potential Edge in CD47 Chase | Frank Vinluan | 09/04/20 | National |
| Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally | Frank Vinluan | 09/03/20 | Boston |
| Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs | Frank Vinluan | 09/02/20 | Seattle |
| Gilead Sciences Places $120M Bet on a Jounce Therapeutics Cancer Drug | Frank Vinluan | 09/01/20 | San Francisco |
| Nestlé to Swallow Up Peanut Allergy Drug Maker Aimmune in $2.6B Deal | Frank Vinluan | 08/31/20 | San Francisco |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Acadia Pharma Acquires CerSci, Potential Pain Meds in $52.5M Buyout | Sarah de Crescenzo | 08/26/20 | San Diego |
| Yumanity to Merge With Proteostasis to Advance Neuro Drug Pipeline | Frank Vinluan | 08/24/20 | Boston |
| J&J Boosts Autoimmune Disease Drug Pipeline With $6.5B Momenta Buyout | Frank Vinluan | 08/19/20 | New York |
| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections | Frank Vinluan | 08/12/20 | Europe |
| AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact | Frank Vinluan | 08/07/20 | Boston |
| Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More | Sarah de Crescenzo | 08/07/20 | National |
| As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up | Frank Vinluan | 08/05/20 | New York |
